News & Updates
Breaking news
Instantly share innovative technologies, product applications, and industry perspectives.
Explore the latest developments in bio-fermentation and precision nutrition.
- Home
- News
- Media reports
- DaBomb completes board re-election; develops poultry product line.
DaBomb completes board re-election; develops poultry product line.
DaBomb (6578) yesterday (28th) at its annual shareholders' meeting approved the 2022 annual report, financial statements, and loss compensation plan. The meeting also approved a cash distribution plan from capital reserves and completed a full re-election of directors and independent directors, with Liu Yu-fen continuing as chairman. DaBomb revenue last year was NT$434 million, a 7.86% decrease year-on-year, and its full-year loss was NT$44.66 million, but this was a 28% reduction compared to the previous year's loss.
DaBomb stated that the company adjusted its order structure, leading to increased shipments of high-value-added products, and its gross profit margin improved quarter by quarter last year. While revenue in the first quarter of this year decreased by 14% year-on-year, the gross profit margin was 4.43%, an increase of 3.79 percentage points compared to the same period last year, indicating that the strategy of optimizing the product mix is gradually taking effect.
Liu Yufen pointed out that the company possesses globally leading fermentation technology for lactic acid bacteria, and has passed the EU's highest standards of HACCP, ISO22000 and FAMI-QS triple certification. Its products are sold all over the world, and it cooperates with large distributors and agents in Asian countries such as China, Japan, South Korea, the Philippines, Thailand, Vietnam, and Malaysia to sell Sheng (Yuetai) protein, enzymes and other products.
Liu Yu-fen also pointed out that in early June, the Tainan Science and Technology Factory passed a factory inspection by a large American global marketing international animal health and nutrition strategy company. Shipments of high-margin enzyme products will continue to grow. The client is committed to developing and selling animal health products with high market demand, such as enzymes and amino acids, involving poultry, pigs, cattle and aquatic products. In the future, we can expect more cooperation between the company and the client.
DaBomb stated that Kuo-Huan Enterprise Group, one of the company's original shareholders, participated in the company's first private placement of common stock this year, becoming the largest single shareholder. Kuo-Huan Enterprise Group is Taiwan's largest animal product distributor with a complete distribution network in Taiwan. The strategic alliance with the company will help increase the company's domestic sales volume and improve market penetration. The company is currently developing poultry products, and leveraging Kuo-Huan Enterprise Group's distribution channels will accelerate its expansion in the domestic market.
In addition, the list of seven newly elected directors (including four independent directors) includes Liu Yufen, representative of Jiaying Investment Co., Ltd., Guohuan Enterprise Co., Ltd., Guojing Enterprise Co., Ltd., and independent directors Huang Huawei, Zhang Yongfu, Zhang Zhi, and Xu Lubing, who were successfully elected for a term of three years.
The above content is excerpted from a MoneyDJ news report dated June 29, 2023, at 8:44:12 AM.
https://www.moneydj.com/kmdj/news/newsviewer.aspx?a=7f7d7e46-9417-4ba5-a50f-445886385158
